From Laboratory Discovery to Future Medicines: The SPT Peptide Research Catalogue Explained

Introduction

Peptides are short chains of amino acids that can act as highly specific biological signals. Naturally occurring peptides help regulate metabolism, growth, tissue repair, immune activity, pigmentation, reproduction, sleep and communication between the brain and other organs.

Scientists can reproduce natural peptides, modify their structures or create peptide-inspired molecules to investigate particular receptors and biological pathways. Some peptide medicines have progressed through clinical trials and received regulatory approval for specific conditions. Others remain experimental, with evidence limited to laboratory studies, animal models or early clinical research.

This guide examines the compounds currently represented in the SPT Peptide catalogue. It explains their scientific background, what researchers have investigated and what their potential future significance might be if safety and effectiveness are eventually established through properly controlled clinical trials.

Research notice: This article is for scientific and educational purposes only. It is not medical advice, a treatment recommendation or a dosing guide. Inclusion does not establish that a compound is safe, effective or approved for human use. SPT catalogue materials are supplied strictly for authorised laboratory research and are not for human or veterinary consumption.

Understanding research evidence

Research evidence can be considered in several broad stages:

Approval of one pharmaceutical formulation does not automatically make every version, strength, salt form or research-grade preparation an approved medicine.

Growth hormone and endocrine research

HGH 191 Somatropin

Somatropin is a laboratory-produced form of the 191-amino-acid human growth hormone naturally released by the pituitary gland. Growth hormone activates its receptor and influences IGF-1 production, growth, metabolism and tissue development.

Licensed pharmaceutical somatropin is already used under medical supervision for specific growth-hormone disorders. Research also examines muscle protein turnover, bone biology, connective-tissue remodelling, recovery mechanisms and age-related changes in growth-hormone signalling.

Future research may improve understanding of how growth-hormone pathways could be targeted more selectively while avoiding metabolic, cardiovascular and abnormal-growth risks. This does not mean somatropin is approved as a general anti-ageing, bodybuilding or performance-enhancement product.

GHRP-2

GHRP-2 is a synthetic growth-hormone secretagogue that interacts principally with the ghrelin receptor, also known as GHS-R1a. It was developed to study how ghrelin-related signals influence pituitary growth-hormone release.

Research has examined pulsatile growth-hormone secretion, appetite signalling, energy balance and endocrine function. If a future medicine demonstrated an acceptable safety profile, it might provide researchers with a way to stimulate endogenous hormonal signalling rather than supplying growth hormone directly. It is not presently an established general therapy.

GHRP-6

GHRP-6 is another synthetic ghrelin-receptor agonist and one of the earlier growth-hormone-releasing peptides. It is particularly associated with research into growth-hormone secretion and appetite.

Studies have explored pituitary responses, ghrelin biology, food-intake signalling and metabolic regulation. Future clinical relevance would depend on demonstrating that useful endocrine effects can be separated from unwanted effects on appetite, glucose regulation and other ghrelin-controlled systems.

CJC-1295 without DAC

CJC-1295-type compounds are synthetic analogues of growth hormone-releasing hormone. The “No DAC” form is designed to have a shorter biological duration than the version attached to a drug-affinity complex.

Researchers use these molecules to investigate growth-hormone pulses, pituitary signalling and downstream IGF-1 biology. Potential future applications could involve carefully controlled endocrine disorders, but long-term benefits and risks have not been established for general health, recovery or anti-ageing purposes.

Sermorelin acetate

Sermorelin is a synthetic fragment of naturally occurring growth hormone-releasing hormone. It binds to pituitary GHRH receptors and was developed to assess or stimulate growth-hormone secretion.

It has a history of pharmaceutical investigation and previous medical use in certain markets. Research continues around pituitary function and endogenous growth-hormone pulsatility. Any broader future application would require modern controlled trials and regulatory review.

Ipamorelin

Ipamorelin is a selective growth-hormone secretagogue that acts through the ghrelin receptor. It was designed to investigate whether growth-hormone release could be stimulated with less activity at some of the hormonal pathways affected by earlier secretagogues.

Preclinical and limited clinical research has examined growth-hormone release, gastrointestinal function, bone biology and recovery-related pathways. Its possible future value would depend on demonstrating meaningful clinical outcomes and long-term endocrine safety.

Tesamorelin

Tesamorelin is a stabilised analogue of growth hormone-releasing hormone. It stimulates pituitary growth-hormone release and increases downstream IGF-1 signalling.

A prescription form is approved in the United States for reducing excess abdominal fat in adults with HIV-associated lipodystrophy. This is a specific medical indication and does not represent general approval for weight loss, muscle gain or anti-ageing.

Researchers continue to investigate metabolic health, liver-fat biology and body-composition changes. Future indications would require separate clinical evidence and regulatory approval.

IGF-1 LR3

IGF-1 LR3 is a modified, longer-acting laboratory analogue of insulin-like growth factor 1. IGF-1 participates in cell growth, survival, metabolism and tissue development.

It is widely used as an experimental tool in cell and animal studies involving muscle biology, neuronal development, glucose handling and tissue growth. Because IGF-1 signalling also influences uncontrolled cellular proliferation, any potential therapeutic development would require particularly careful safety evaluation.

PEG-MGF

Mechano-growth factor is an alternatively spliced form associated with the IGF-1 system and has been studied in mechanically stressed tissue. PEG-MGF refers to a pegylated experimental analogue intended to prolong stability.

Research has focused on satellite cells, skeletal-muscle adaptation and tissue-repair signalling. Evidence remains primarily experimental. Any future therapeutic potential would depend on reproducible human evidence, manufacturing consistency and careful evaluation of abnormal-growth risks.

Human chorionic gonadotropin — HCG

HCG is a naturally occurring glycoprotein hormone produced during pregnancy. It acts similarly to luteinising hormone and influences reproductive endocrine signalling.

Licensed HCG medicines already have specific fertility and hormonal uses under professional supervision. Research also examines reproductive biology, testicular signalling and endocrine diagnostics. Existing approvals should not be interpreted as support for unsupervised performance or body-composition use.

Kisspeptin-10

Kisspeptin-10 is an active fragment of kisspeptin, a natural regulator of the hypothalamic–pituitary–gonadal axis. It stimulates GnRH signalling and therefore influences downstream reproductive hormones.

Clinical research has examined puberty, fertility, ovulation and reproductive-hormone disorders. If future studies establish reliable clinical outcomes, kisspeptin-based medicines could potentially provide more physiologically targeted approaches to selected fertility conditions.

Oxytocin acetate

Oxytocin is a naturally occurring peptide hormone involved in uterine contraction, milk release and several forms of social and neurological signalling.

Prescription oxytocin already has established obstetric uses. Separate research investigates social cognition, stress responses, attachment, anxiety and neurodevelopmental biology, but results have been mixed and strongly dependent on context.

Future neurological applications would require convincing evidence that targeted oxytocin signalling provides consistent benefit without inappropriate endocrine or cardiovascular effects.

Metabolic research

Semaglutide

Semaglutide is a modified GLP-1 receptor agonist. GLP-1 signalling influences glucose-dependent insulin release, glucagon activity, appetite and gastric emptying.

Licensed semaglutide medicines are already approved for specific conditions including type 2 diabetes and weight management, depending on the formulation and jurisdiction. Research-grade semaglutide is not interchangeable with an authorised prescription medicine.

Ongoing studies examine cardiovascular, kidney, liver and neurodegenerative disease outcomes. Future benefits must be established separately for each condition through regulated clinical trials.

Tirzepatide

Tirzepatide is a dual GIP and GLP-1 receptor agonist developed to influence complementary incretin pathways.

Authorised pharmaceutical products are already prescribed for specific metabolic indications, including type 2 diabetes and weight management in relevant jurisdictions. Its research has demonstrated how multi-receptor signalling can produce substantial effects on glucose regulation, appetite and body weight.

Current research is exploring cardiovascular outcomes, sleep apnoea, liver disease and other metabolic complications. Those possible applications should not be treated as approved until regulators have reviewed the relevant evidence.

Retatrutide

Retatrutide is an investigational triple-receptor agonist targeting GLP-1, GIP and glucagon receptors. It was designed to combine appetite regulation and glucose control with glucagon-related effects on energy expenditure and liver metabolism.

Clinical trials have investigated obesity, type 2 diabetes and metabolic liver disease. If late-stage trials confirm an acceptable balance of effectiveness and safety, retatrutide could become an important multi-pathway metabolic medicine. Until regulatory approval occurs, it remains investigational.

Cagrilintide

Cagrilintide is a long-acting analogue of amylin, a pancreatic peptide that contributes to satiety, meal-related signalling and gastric emptying.

Researchers have studied cagrilintide alone and in combination with GLP-1 receptor agonists for weight management. Its potential future significance lies in targeting complementary appetite pathways, but approval will depend on complete trial results and regulatory assessment.

AOD9604

AOD9604 is a modified fragment derived from the C-terminal region of human growth hormone. It was developed to investigate whether metabolic effects associated with fat biology could be separated from the broader growth-promoting actions of growth hormone.

Research has examined adipose tissue and lipid metabolism, but clinical evidence has not established it as an approved weight-management treatment. Future relevance would require clear evidence of clinically meaningful outcomes rather than laboratory changes alone.

5-Amino-1MQ

5-Amino-1MQ is not a peptide. It is a small-molecule inhibitor studied in relation to nicotinamide N-methyltransferase, or NNMT.

Preclinical research has explored fat-cell metabolism, energy balance and age-related metabolic changes. Its proposed future relevance concerns metabolic and cellular-energy pathways, but human safety and effectiveness remain insufficiently established.

MOTS-c

MOTS-c is a mitochondrial-derived peptide encoded within mitochondrial genetic material. It has attracted attention because it may help coordinate communication between mitochondria and the rest of the cell.

Preclinical research investigates insulin sensitivity, glucose metabolism, cellular stress responses, exercise biology and ageing. If translated successfully into human medicine, MOTS-c-related research might contribute to treatments targeting metabolic dysfunction or loss of cellular resilience.

NAD+

Nicotinamide adenine dinucleotide is not a peptide. It is a coenzyme essential to energy metabolism, redox reactions, DNA-repair systems and cellular signalling.

Research into NAD+ biology examines ageing, mitochondrial function and metabolic disease. Although NAD+ pathways are biologically important, claims that externally supplied NAD+ reverses ageing or treats broad conditions are not established. Future benefits may come from precisely targeting particular NAD+-dependent pathways rather than making general “anti-ageing” claims.

L-Carnitine

L-carnitine is an amino-acid-derived nutrient, not a peptide. It helps transport long-chain fatty acids into mitochondria, where they can contribute to energy production.

Licensed preparations have recognised uses in particular forms of carnitine deficiency. Research also examines exercise metabolism, cardiovascular biology and mitochondrial disorders, although findings differ across populations. It should not be represented as a novel experimental peptide.

Lipo-C with B12

Lipo-C with B12 is a compounded nutrient mixture rather than a single peptide. Formulations can differ and may contain lipotropic nutrients alongside vitamin B12.

Research into its individual ingredients concerns normal nutrient metabolism and deficiency correction. Claims regarding weight loss, fat burning or energy enhancement depend on the precise formulation and are not established merely because the ingredients participate in metabolism.

Recovery and tissue-repair research

BPC-157

BPC-157 is a synthetic 15-amino-acid fragment derived from a protective gastric protein sequence. Most published research has involved cells and animal models rather than large controlled human trials.

Researchers have investigated tendon, ligament and muscle injury models, gastrointestinal protection, blood-vessel signalling and inflammatory responses. These findings do not demonstrate that BPC-157 heals injuries in humans.

If future clinical trials establish safety and effectiveness, its greatest potential may lie in understanding tissue-protective signalling and difficult-to-treat connective-tissue or gastrointestinal injuries. It currently remains investigational.

TB-500

TB-500 is a synthetic research compound associated with regions of thymosin beta-4, a naturally occurring peptide involved in actin regulation, cell movement and wound biology.

Research into thymosin beta-4-related pathways has examined cell migration, blood-vessel formation, corneal repair, cardiac injury and tissue remodelling. Commercial TB-500 should not automatically be treated as identical to full-length pharmaceutical thymosin beta-4.

Future therapeutic development would require precise structural identification, controlled manufacturing and human clinical evidence.

ARA-290 — Cibinetide

ARA-290, also known as cibinetide, is an engineered peptide derived from part of erythropoietin. It was designed to investigate tissue-protective signalling without strongly stimulating red-blood-cell production.

Clinical research has examined inflammatory injury and small-fibre neuropathy, including conditions such as sarcoidosis. Potential future value could involve neuropathic or inflammatory disorders, but larger confirmatory studies are required.

KPV

KPV is a three-amino-acid fragment associated with alpha-melanocyte-stimulating hormone. It is studied for signalling related to inflammation without the full pigmentation activity of the parent hormone.

Laboratory and animal research has examined inflammatory pathways, intestinal barrier function, skin biology and immune responses. Its future relevance could involve local inflammatory or barrier disorders, but dependable human evidence is still limited.

Immune-signalling research

Thymosin alpha-1

Thymosin alpha-1 is a 28-amino-acid peptide originally isolated from thymic tissue. It influences dendritic cells, T-cell activity and innate immune signalling.

It has authorised medical uses in certain countries, but approval differs by jurisdiction and indication. Research has examined chronic infection, immune dysfunction, sepsis and responses alongside cancer therapies.

Possible future applications would require condition-specific evidence demonstrating that immune modulation improves outcomes without producing harmful immune activation.

LL-37

LL-37 is a naturally occurring human antimicrobial peptide produced from the cathelicidin precursor. It contributes to innate defence, microbial responses, inflammation and wound biology.

Research investigates antimicrobial activity, biofilms, skin repair and immune regulation. LL-37 can also promote excessive inflammation under some conditions, so its biology is not simply beneficial.

Future medicines may attempt to reproduce selected antimicrobial actions or regulate LL-37 pathways while avoiding inflammatory and tissue-damaging effects.

VIP — Vasoactive intestinal peptide

VIP is a naturally occurring neuropeptide involved in smooth-muscle relaxation, blood-vessel regulation, intestinal function, immune signalling and communication within the nervous system.

Research has examined pulmonary hypertension, inflammatory disease, respiratory injury and neurological signalling. Because VIP acts across many organs and is rapidly broken down, future development may depend on targeted delivery or more stable receptor-selective analogues.

Cognitive and neurological research

DSIP

Delta sleep-inducing peptide was originally isolated during investigations into sleep regulation. Its precise physiological role remains uncertain and historical findings have not always been consistently reproduced.

Research has explored sleep architecture, stress responses, pain signalling and neuroendocrine activity. Future significance depends on establishing its biological target and producing convincing controlled clinical evidence.

Selank

Selank is a synthetic peptide derived from the naturally occurring immunomodulatory peptide tuftsin. It has been investigated mainly in Russia and neighbouring research systems.

Studies have considered anxiety-related behaviour, stress responses, neurotransmitter systems and immune–brain communication. Wider clinical acceptance would require larger independently replicated trials using internationally recognised standards.

Semax

Semax is a synthetic peptide related to part of the adrenocorticotropic hormone sequence but designed without the parent hormone’s principal endocrine activity.

Research has investigated neuroprotection, cerebral blood flow, stroke recovery, attention and learning. It has a history of use in some countries, but is not broadly approved by major UK, European or US regulators. Future adoption would require robust international clinical evidence.

Pinealon

Pinealon is a short synthetic tripeptide investigated within the field of peptide bioregulation. Research claims have focused on neuronal gene expression, oxidative stress and cognitive ageing.

The evidence base is limited and much of it comes from a relatively narrow group of researchers. Its future significance remains hypothetical until independently replicated studies establish mechanism, safety and meaningful clinical outcomes.

Longevity and mitochondrial research

Epitalon — Epithalon

Epitalon is a synthetic tetrapeptide associated with research into pineal biology and peptide bioregulation.

Laboratory and small exploratory studies have examined telomerase activity, circadian biology, oxidative stress and ageing-related processes. These findings do not establish that Epitalon extends human lifespan or reverses ageing.

If future research proves a clinically useful effect, it may improve understanding of cellular ageing or circadian regulation. Long-term safety and independent replication would be essential.

SS-31 — Elamipretide

SS-31, also called elamipretide, is a mitochondria-targeted tetrapeptide designed to interact with cardiolipin in the inner mitochondrial membrane.

Clinical programmes have examined mitochondrial disease, cardiac and skeletal-muscle function and age-related mitochondrial decline. Results have varied across conditions. Its potential lies in stabilising mitochondrial energy production, but any benefit must be demonstrated for each individual disease.

FOXO4-DRI

FOXO4-DRI is an experimental cell-penetrating peptide designed to disrupt an interaction involving FOXO4 and p53 in senescent cells.

Early animal research suggested that manipulating this pathway might encourage selected senescent cells to undergo programmed cell death. Evidence remains preclinical, and removing senescent cells can carry significant biological risks.

Future senolytic development may help researchers understand age-related tissue dysfunction, but FOXO4-DRI is far from being an established human longevity treatment.

Testagen

Testagen is described as a short peptide bioregulator associated with endocrine and age-related research. Published evidence is limited, and product terminology can vary between suppliers.

Proposed research areas include gene regulation, reproductive-tissue biology and age-related endocrine changes. Claims of immune restoration, hormone enhancement or healthy-ageing benefits require stronger independent evidence.

Your existing product link currently uses /product/thymalin, while the visible product is called “Testagen 20mg.” These names should be checked because Testagen and Thymalin should not automatically be treated as the same compound.

Melanocortin and cosmetic research

Melanotan 1

Melanotan 1 is commonly used to refer to a synthetic analogue of alpha-melanocyte-stimulating hormone. A closely related regulated medicine, afamelanotide, has specific approval for erythropoietic protoporphyria in certain jurisdictions.

Research focuses on melanocortin-1 receptor signalling, melanin production and protection from light-related cellular damage. This does not make general tanning products approved or safe.

Future research may extend understanding of photoprotection and pigment disorders, but any medicine would require controlled formulation and medical oversight.

Melanotan 2

Melanotan 2 is a synthetic cyclic melanocortin analogue that can interact with several melanocortin receptor subtypes.

Research has examined pigmentation, appetite, energy balance and sexual-response pathways. Its lack of receptor selectivity can also produce unpredictable effects. It is not an approved cosmetic tanning medicine.

Future melanocortin medicines may benefit from greater receptor selectivity, allowing researchers to target one biological function while reducing unwanted activity elsewhere.

PT-141 — Bremelanotide

PT-141, known pharmaceutically as bremelanotide, is a melanocortin receptor agonist developed from melanotan-related research.

A regulated bremelanotide medicine has a specific US approval for acquired, generalised hypoactive sexual desire disorder in certain premenopausal women. Approval and availability differ by jurisdiction.

Research continues into central melanocortin signalling and sexual-response biology. Existing approval must not be expanded into unsupported claims for other populations or conditions.

GHK-Cu

GHK-Cu is a naturally occurring copper-binding tripeptide found in human plasma and other biological fluids. Its levels and biological roles have been studied in relation to tissue remodelling.

Research has explored collagen and extracellular-matrix biology, wound repair, antioxidant responses, hair-follicle signalling and skin appearance. Much of its commercial use is topical and cosmetic rather than an approved systemic peptide treatment.

Future research may identify more precise dermatological or wound-care applications, provided formulation, delivery and clinical effectiveness are established.

SNAP-8

SNAP-8, also known as acetyl octapeptide-3, is a synthetic cosmetic peptide inspired by part of the SNAP-25 protein involved in neurotransmitter release.

It is commonly studied and marketed as a topical cosmetic ingredient intended to affect the appearance of expression lines. Evidence is primarily cosmetic and formulation-dependent. It is not equivalent to a medically approved neuromuscular treatment.

Lemon Bottle

Lemon Bottle is a branded cosmetic mixture, not a peptide. Its composition and regulatory status must be assessed from the manufacturer’s current documentation.

It should not be described as peptide science. Claims concerning local fat reduction require credible clinical evidence for the exact finished formulation, not simply evidence relating to individual ingredients.

Research stacks

Wolverine Stack

“Wolverine Stack” is a commercial research blend rather than a new peptide. It generally refers to BPC-157 and a TB-500-related compound.

The scientific questions relate to whether separate tissue-repair pathways could interact. However, combining experimental compounds increases uncertainty and does not prove enhanced effectiveness or safety.

The product page should disclose the exact compounds and quantities rather than relying only on the stack name.

Glow Stack

Glow Stack is a research blend commonly associated with GHK-Cu, BPC-157 and a TB-500-related compound. It brings together experimental pathways involving connective tissue, skin biology and cellular migration.

The combination itself should not be described as clinically proven. Its product page should list every ingredient, amount and relevant batch certificate.

Klow Stack

Klow Stack combines BPC-157, a TB-500-related compound, GHK-Cu and KPV. The catalogue formulation is represented as a combined recovery, skin and inflammatory-signalling research stack.

Each ingredient has a different proposed mechanism, but evidence relating to one component cannot establish the effectiveness or safety of the complete mixture. Combination-specific research would be necessary.

Research accessories

Bacteriostatic water

Bacteriostatic water is not a peptide. It is sterile water containing a preservative, commonly benzyl alcohol, and is manufactured for specific laboratory or pharmaceutical applications.

It should appear under Research Accessories, not within peptide research categories. Its certificate should confirm identity, sterility-related specifications and preservative concentration where applicable.

What could future peptide medicines offer?

The future value of peptide science is not that every experimental compound will become a medicine. Most investigational molecules do not successfully complete the full development process.

The real promise lies in selectivity. Peptides may allow researchers to communicate with particular receptors or biological pathways more precisely than less targeted compounds.

Potential future advances may include:

More selective metabolic medicines that address several complementary pathways. Tissue-repair treatments supported by controlled human evidence. Mitochondria-targeted therapies for specific inherited or acquired diseases. New approaches to inflammatory and immune disorders. Better treatments for reproductive and endocrine dysfunction. Receptor-selective melanocortin medicines. Targeted neurological medicines with improved delivery into the nervous system. Dermatological peptides supported by formulation-specific clinical trials.

However, possible benefit must always be assessed alongside toxicity, immune reactions, contamination risks, endocrine disruption, abnormal cellular growth and long-term effects.

Conclusion

Peptide research connects metabolism, endocrinology, neuroscience, immunology, mitochondrial biology, tissue repair and dermatology. Some compounds in the SPT catalogue are related to established prescription medicines, while others remain at an early experimental stage.

The responsible approach is to describe what has actually been studied, identify the level of evidence and avoid presenting preclinical findings as proven human benefits.

As research progresses, some of these molecules may help scientists develop future medicines. Others may remain useful laboratory tools without becoming clinical treatments. Both outcomes can contribute valuable knowledge to peptide science.

Final research notice: No investigational compound discussed in this guide should be assumed safe or effective for personal use. Regulatory approval applies only to the exact authorised medicine, formulation, indication and patient population. SPT Peptide materials are offered strictly for authorised research and analytical purposes.